RAS as Supporting Actor in Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• RAS proteins are critical oncogenic drivers in numerous cancers, but their role in breast cancer has been historically underestimated due to low mutation frequencies.
• Recent research indicates RAS pathway engagement is essential for breast cancer progression, metastasis, and therapeutic resistance, irrespective of direct mutation.
• This underscores a complex, indirect role for RAS in breast tumorigenesis.

Purpose of the Study:

• To review the literature on the role of RAS proteins in breast cancer over the past three decades.
• To explore the controversial involvement and mutation status of RAS in breast tumorigenesis.
• To elucidate the function of RAS as a supporting factor rather than a primary driver in breast cancer.

Main Methods:

• Comprehensive literature review of studies spanning 30 years.
• Analysis of research investigating RAS protein function and mutation status in breast cancer.
• Synthesis of findings on RAS involvement in tumor initiation, progression, metastasis, and therapy resistance.

Main Results:

• RAS oncogenic mutations are infrequent in human breast lesions, contrasting with other cancers.
• RAS pathway activation is indispensable for breast cancer progression, metastatic spread, and resistance to therapies.
• RAS proteins function as critical facilitators ('supporting actors') in breast cancer development, downstream of other oncogenic alterations.

Conclusions:

• The role of RAS in breast cancer is complex, acting as a key mediator of tumor progression and resistance.
• Targeting the RAS pathway presents a promising therapeutic strategy for breast cancer, even in the absence of direct RAS mutations.
• Future research should focus on understanding how RAS is engaged downstream of various oncogenic events in breast cancer.